+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tofacitinib Citrate Extended-Release Tablets Market by Indication, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Tofacitinib Citrate Extended-Release Tablets Market by Indication, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Tofacitinib Citrate Extended-Release Tablets Market by Indication, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082105
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The extended-release Tofacitinib Citrate market is undergoing rapid transformation as pharmaceutical innovations target better patient adherence, sustained therapeutic results, and evolving regional regulatory landscapes. Senior leaders seeking an in-depth outlook on this segment will find critical analysis of new drug formulations, market-defining policy shifts, and competitive strategies designed to optimize reach and value.

Market Snapshot: Extended-Release Tofacitinib Citrate

Market demand for extended-release Tofacitinib Citrate is fueled by rising chronic autoimmune diagnoses and the need for patient-friendly dosing regimens. Innovations in drug delivery now allow for sustained therapeutic effects, directly addressing pain points in adherence and patient management. The market currently reflects reshaped channel strategies, evolving payer frameworks, and growing emphasis on lifecycle management as tariff and supply-chain pressures intensify.

Scope & Segmentation

  • Indications: Target segments include psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis—each with unique growth prospects linked to diagnosis rates and ongoing therapy requirements.
  • Distribution Channels: The value chain spans hospital pharmacies (private and public), online pharmacies, retail pharmacies (chains and independents), and specialty pharmacies, covering both hospital-owned and independent networks.
  • End Users: Utilization patterns vary across ambulatory care centers, hospitals, and specialty clinics, each optimizing dosing and ongoing management within integrated care models.
  • Patient Age Groups: Core adult populations anchor demand, while tailored protocols and growing approvals drive usage among geriatric and pediatric patients.
  • Regions: Coverage includes major and emerging markets within the Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (such as United Kingdom, France, Germany, Saudi Arabia, South Africa, Turkey, and others), and Asia-Pacific (including China, Japan, India, Australia, Indonesia, Singapore, South Korea, Vietnam, and more).
  • Company Coverage: Profiles include Pfizer Inc., Teva Pharmaceuticals USA, Mylan Pharmaceuticals, Sandoz Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories, Lupin, Glenmark, Apotex Corp., and Cipla Limited.

Key Takeaways for Decision-Makers

  • Extended-release formulations are improving patient adherence by minimizing dosing fluctuations and are supported by a robust pipeline of clinical validation.
  • Regulators are accelerating approvals for novel drug delivery solutions, which strengthens lifecycle management and creates competitive momentum.
  • Payer and provider focus on outcome-driven therapy has led to increased adoption of value-based agreements and differentiated pricing models.
  • Patient segmentation—by indication and age group—drives specialized strategies for market entry, distribution, and tailored patient support programs.
  • Digital health tools and specialty pharmacy partnerships are emerging as key platforms supporting adherence, patient engagement, and enhanced care coordination.

Tariff Impact on Supply Chains

Anticipated United States tariff changes in 2025 are increasing costs for imported active pharmaceutical ingredients, prompting manufacturers to adapt sourcing and distribution. Companies are offsetting these pressures by relocating production steps nearer to end markets, renegotiating supplier contracts, and diversifying their raw materials pipeline. These responses often call for infrastructure investment and heightened collaboration between regulatory, commercial, and supply-chain functions, ensuring continuous market access and mitigating risk of shortages or pricing volatility.

Methodology & Data Sources

This market analysis integrates both primary and secondary research. Insights from pharmacy leaders, regulatory experts, and key payers are complemented by peer-reviewed studies, proprietary data sources, and industry filings. Data triangulation ensures accuracy in market sizing, competitive mapping, and segmentation analysis. Sensitivity checks track the impact of tariffs and regulatory updates, while transparency on research limitations underscores the credibility of findings.

Why This Report Matters

  • Enables informed strategic planning by arming decision-makers with actionable insights on evolving opportunities, risks, and regional pathway differences.
  • Delivers granular segmentation data to help prioritize indications, distribution channels, and end-user environments based on underlying regional and clinical dynamics.
  • Highlights the operational effects of tariffs, real-world evidence initiatives, and competitive entry timing to support agile, risk-mitigated business decisions.

Conclusion

The extended-release Tofacitinib Citrate market is shaped by patient-centric innovation, sophisticated supply networks, and dynamic regulatory environments. This report guides senior leaders in anticipating disruptions and aligning strategy with evolving global market opportunities.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tofacitinib Citrate Extended-Release Tablets Market, by Indication
8.1. Introduction
8.2. Psoriatic Arthritis
8.3. Rheumatoid Arthritis
8.4. Ulcerative Colitis
9. Tofacitinib Citrate Extended-Release Tablets Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Private Hospital Pharmacy
9.2.2. Public Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
9.5. Specialty Pharmacy
9.5.1. Hospital Owned Specialty Pharmacy
9.5.2. Independent Specialty Pharmacy
10. Tofacitinib Citrate Extended-Release Tablets Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Tofacitinib Citrate Extended-Release Tablets Market, by Patient Age Group
11.1. Introduction
11.2. Adults
11.3. Geriatric
11.4. Pediatric
12. Americas Tofacitinib Citrate Extended-Release Tablets Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Teva Pharmaceuticals USA, Inc.
15.3.3. Mylan Pharmaceuticals, Inc.
15.3.4. Sandoz Inc.
15.3.5. Aurobindo Pharma Limited
15.3.6. Dr. Reddy’s Laboratories Limited
15.3.7. Lupin Limited
15.3.8. Glenmark Pharmaceuticals Limited
15.3.9. Apotex Corp.
15.3.10. Cipla Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET MULTI-CURRENCY
FIGURE 2. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET MULTI-LANGUAGE
FIGURE 3. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL OWNED SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 51. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 52. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 53. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 59. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. GERMANY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 95. GERMANY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 96. GERMANY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. FRANCE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. FRANCE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. FRANCE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 101. FRANCE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 102. FRANCE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 103. FRANCE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. FRANCE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. ITALY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. ITALY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ITALY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 115. ITALY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 116. ITALY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 117. ITALY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. ITALY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. SPAIN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. SPAIN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. SPAIN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 122. SPAIN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 123. SPAIN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 124. SPAIN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SPAIN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. DENMARK TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. DENMARK TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. DENMARK TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. QATAR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. QATAR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. QATAR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 164. QATAR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 165. QATAR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 166. QATAR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. QATAR TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. FINLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. FINLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. FINLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 171. FINLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 172. FINLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 173. FINLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FINLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. EGYPT TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. EGYPT TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. EGYPT TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. EGYPT TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. EGYPT TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 194. EGYPT TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. EGYPT TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. TURKEY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. TURKEY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. TURKEY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 199. TURKEY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 200. TURKEY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 201. TURKEY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. TURKEY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 210. NORWAY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NORWAY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 213. NORWAY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 214. NORWAY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 215. NORWAY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. NORWAY TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. POLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. POLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. POLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 220. POLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 221. POLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 222. POLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. POLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 243. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 244. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 249. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 250. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 251. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 256. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 257. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tofacitinib Citrate Extended-Release Tablets market report include:
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Mylan Pharmaceuticals, Inc.
  • Sandoz Inc.
  • Aurobindo Pharma Limited
  • Dr. Reddy’s Laboratories Limited
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited
  • Apotex Corp.
  • Cipla Limited

Related Topics

Related Reports

Tofacitinib Market Report 2025 - Product Image

Tofacitinib Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Doxazosin Mesylate Extended Release Tablets Market by Indication, Distribution Channel, Strength, End User, Patient Age Group, Payment Type - Global Forecast to 2030 - Product Image

Doxazosin Mesylate Extended Release Tablets Market by Indication, Distribution Channel, Strength, End User, Patient Age Group, Payment Type - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Sitagliptin Metformin Extended Release Tablets Market by Dosage Strength, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Sitagliptin Metformin Extended Release Tablets Market by Dosage Strength, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Clarithromycin Tablets Market Report 2025 - Product Image

Clarithromycin Tablets Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Tramadol Hydrochloride Tablet Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Tramadol Hydrochloride Tablet Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.